Soleo Health, a national provider of specialty home and alternate-site infusion services, has been selected by Roche’s Genentech to dispense two limited distribution drugs, Hemlibra and Ocrevus.  Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from the Food and Drug Administration (FDA) in November 2017. Ocrevus (ocrelizumab) is used for patients with relapsing or primary progressive forms of multiple…